Skip to main content
. 2019 Nov 4;18(6):4617–4624. doi: 10.3892/etm.2019.8166

Figure 2.

Figure 2.

Bcl-2 is a direct target gene of miR-195-5p. (A) TargetScan software was used to predict a binding site for miR-195-5p in the 3′UTR of Bcl-2. (B) Luciferase activity of a dual-luciferase reporter vector containing wild-type 3′UTR-Bcl-2 or a mutant 3′UTR-Bcl-2. Data are presented as the mean ± SD of three independent experiments. (C) The mRNA expression levels of Bcl-2 in the peripheral blood from 15 healthy volunteers (Control) and in the peripheral blood from 15 DVT patients using reverse transcription-quantitative PCR. (D) Representative western blotting of Bcl-2 in the peripheral blood from 2 healthy volunteers (Control) and in the peripheral blood from 2 DVT patients. (E) The ratio of Bcl-2/β-actin was calculated in the different groups. WT, wild-type; MUT, mutant-type; WT-Bcl-2, HUVECs co-transfected with WT 3′UTR-Bcl-2 and either mimic control or miR-195-5p; MUT-Bcl-2, HUVECs transfected with MUT 3′UTR-Bcl-2. Data are presented as the mean ± SD. **P<0.01 vs. mimic control; ##P<0.01 vs. control. DVT, deep vein thrombosis; HUVECs, human umbilical vein endothelial cells; UTR, untranslated region; miR, microRNA.